HONORHEALTH SCOTTSDALE THOMPSON PEAK
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $1.7M
- Transactions
- 144
- Companies
- 22
- Average per transaction
- $11,965
Who reported the payments
| Genmab U.S., Inc. | $723,815 |
| Sanofi US Services Inc. | $294,127 |
| AstraZeneca | $109,918 |
| Gilead | $84,861 |
| Atricure, Inc. | $79,968 |
| Argenx US, Inc. | $79,498 |
| Astrazeneca UK Limited | $72,826 |
| Institut DE Recherches Servier | $48,608 |
| Sanofi | $45,175 |
| Y-mabs Therapeutics, Inc. | $41,655 |
| Genentech, Inc. | $31,032 |
| Insmed, Inc. | $30,280 |
| Synthorx Inc. | $17,675 |
| Neovasc Medical Inc | $15,000 |
| EMD Serono, Inc. | $12,394 |
| Eli Lilly | $11,451 |
| Acell, Inc. | $8,400 |
| AbbVie | $8,077 |
| Shockwave Medical, Inc | $5,001 |
| Stryker | $1,419 |
| Morphosys AG | $1,000 |
| Rhythm Pharmaceuticals, Inc. | $750 |